Nipocalimab
-
Pharma
Nipocalimab cuts lupus disease activity in Phase 2 trial
Late-breaking data presented at EULAR 2026 showed sustained reductions in systemic lupus erythematosus disease activity through 52 weeks, with the…
Read More » -
Pharma
Nipocalimab shows stronger responses in Sjögren’s disease patients with high autoantibody levels
New Phase 2 analyses presented by Johnson & Johnson suggest that adults with moderate-to-severe Sjögren’s disease and elevated disease-driving autoantibodies…
Read More »
